Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • Resource and Technical Advances
    • Clinical Medicine
    • Reviews
    • Editorials
    • Perspectives
    • Top read articles
  • JCI This Month
    • Current issue
    • Past issues

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Editorials
  • Viewpoint
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Transfers
  • Advertising
  • Job board
  • Contact
Shared recognition of citrullinated tenascin-C peptides by T and B cells in rheumatoid arthritis
Jing Song, … , Eddie A. James, Jane H. Buckner
Jing Song, … , Eddie A. James, Jane H. Buckner
Published January 28, 2021
Citation Information: JCI Insight. 2021;6(5):e145217. https://doi.org/10.1172/jci.insight.145217.
View: Text | PDF
Research Article Immunology

Shared recognition of citrullinated tenascin-C peptides by T and B cells in rheumatoid arthritis

  • Text
  • PDF
Abstract

Tenascin-C (TNC), an extracellular matrix protein that has proinflammatory properties, is a recently described antibody target in rheumatoid arthritis (RA). In this study, we utilized a systematic discovery process and identified 5 potentially novel citrullinated TNC (cit-TNC) T cell epitopes. CD4+ T cells specific for these epitopes were elevated in the peripheral blood of subjects with RA and showed signs of activation. Cit-TNC–specific T cells were also present among synovial fluid T cells and secreted IFN-γ. Two of these cit-TNC T cell epitopes were also recognized by antibodies within the serum and synovial fluid of individuals with RA. Detectable serum levels of cit-TNC–reactive antibodies were prevalent among subjects with RA and positively associated with cyclic citrullinated peptide (CCP) reactivity and the HLA shared epitope. Furthermore, cit-TNC–reactive antibodies were correlated with rheumatoid factor and elevated in subjects with a history of smoking. This work confirms cit-TNC as an autoantigen that is targeted by autoreactive CD4+ T cells and autoantibodies in patients with RA. Furthermore, our findings raise the possibility that coinciding epitopes recognized by both CD4+ T cells and B cells have the potential to amplify autoimmunity and promote the development and progression of RA.

Authors

Jing Song, Anja Schwenzer, Alicia Wong, Sara Turcinov, Cliff Rims, Lorena Rodriguez Martinez, David Arribas-Layton, Christina Gerstner, Virginia S. Muir, Kim S. Midwood, Vivianne Malmström, Eddie A. James, Jane H. Buckner

×

Figure 1

Citrulline residues are required in cit-TNC17 and cit-TNC56 peptides for HLA-DRB1*0401 binding and immunogenicity.

Options: View larger image (or click on image) Download as PowerPoint
Citrulline residues are required in cit-TNC17 and cit-TNC56 peptides for...
(A) The binding of cit-TNC and their counterpart arginine peptides (arg-TNC) to DRB1*04:01 was tested using a peptide competition assay; each peptide was tested in triplicate. Europium-conjugated streptavidin was used to label residual biotinylated peptide bound to the HLA-DR protein. Binding curves were fitted by nonlinear regression with a sigmoidal dose response curve model, and EC50 values were calculated as the peptide concentration needed to displace 50% of the reference peptide. The HA306–318 peptide was used as a positive control. The EC50 cutoff for measurable binding was 50 μM. Results indicated that citrullination at 1 specific residue was required for cit-TNC17 and cit-TNC56 binding. X stands for 1 citrullinated amino acid in cit-TNC; R stands for 1 arginine amino acid in arg-TNC. (B) Citrullination of a distinct T cell contact residue was associated with cit-TNC17 and cit-TNC56 immunogenicity. Representative plots showing representative CD4+ T cell response to TNC peptide citrullinated at either both residues (TNC17XX and TNC56XX) or only 1 residue (TNC17RX and TNC56XR); n = 14 RA subjects tested for all peptides.

Copyright © 2023 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts